Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
Thanks 🙏 Peakhope. I realised that might be the case when I thought about it more carefully.
Agreed, although it is reassuring that Mr. Zamboni doesn’t appear to have too many irons in the fire. SYME investors want him and his key colleagues to give their full attention to bringing SYME to fruition and with it restoring the share price to previous higher levels.
It is odd that his two current positions are not linked on his Companies House profile as is the case with Albert Ganyushin, who is also associated with both companies?
Alessandro Zamboni:
https://find-and-update.company-information.service.gov.uk/officers/-lg_HQIJIYKPSRzsyMc5UfeL604/appointments
Albert Ganyushin:
https://find-and-update.company-information.service.gov.uk/officers/ooP3iAx7aoXLUX4-B5NUvaSTzZE/appointments
Alessandro Zamboni very recently announced on LinkedIn that he has assumed a new position as a NED to the above company. One can immediately see the potential for synergies between SYME and RegTech Open Project. Here is some information about the latter company.
https://regtechopenproject.co.uk/
One question though? Why is he announcing this now when he has been a NED of this company since March 10, 2023?
https://find-and-update.company-information.service.gov.uk/company/14721885/officers
1. Viral respiratory infections continue to offer a therapeutic challenge due to the limited number of effective therapies available, and due to the fact that it is not clear which host response is the most productive for an optimal (and rapid) recovery.
2. Interferon β pathway is impaired in severe respiratory infections and this creates a severe disease burden.
3. Exogenous inhaled interferon has been shown to be beneficial in this setting.
4. Nebulised interferon-β is currently about to be investigated as a potential therapy for multiple severe respiratory infections because the available data from phase II and phase III studies demonstrate that this treatment is able to accelerate the recovery from disease.
5. Further clinical studies will be needed in order to better document i) the efficacy of this therapy, ii) its optimal duration, and iii) if such a medication is appropriate for domiciliary use? Additionally, whether, combined regimens with antivirals, or with compounds which are able to enhance the endogenous production of interferon, might be of promise?
These studies, once commenced, may take a considerable time to bring to a conclusion. Also, Synairgen cannot make a great deal of progress towards bringing SNG001 to market without additional capitation, or better with the financial support, and experience, of a large biopharmaceutical entity. The latter represents the company’s optimal future route to market, bearing in mind what happened during the previous Phase III trial.
The timescale involved is similar to the expected timescale for Synairgen’s parallel P2 trials. The antiviral treatment is targeted to treat the early onset of CV-19.
“RHB-107 accepted for inclusion in ACESO's PROTECT adaptive platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa
The substantial 300-patient Phase 2 study, predominantly funded by the U.S. Government Department of Defense's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), has received FDA clearance to start (expected Q3/23) and is estimated to be completed by end of 2024
If approved, RHB-107, a novel, oral, once-daily, broad-acting, host-directed antiviral is expected to act independently of viral spike protein mutations1, would potentially target a multi-billion-dollar early COVID-19 treatment market
RHB-107 successfully met the primary endpoint of safety and tolerability and delivered promising efficacy results, including marked reduction in hospitalization due to COVID-19 in a U.S. Phase 2 study2”
Dr Flic Gabbay's name does not feature in the 'declaration of interest' list at the end of the article. Perhaps being a NED of a tiny biopharmaceutical entity currently planning five small parallel P2 trials to commence sometime during next Winter doesn't qualify? Would Dr Gabbay need to be a Synairgen shareholder in order to have an interest to declare?
I totally agree Doc.Daneeka. There was no new information from the company to complement the rise. Consequently, it is unsustainable, and the share price should fall to previous levels.
LTIs are hardly likely to take notice of such froth. The share price is currently at around 1/30 of the pre Feb 2022 highs. Consequently, it will take a 3000% rise to restore it to those levels. A temporary 16% rise is of no value to LTIs, although advantageous to day traders who have timed their short term stake appropriately.
My only wish is that Synairgen are by now getting on with arranging the P2 parallel trials. There is no way of knowing that this is actually happening and we have to trust them to keep to their word. I am weary of the CEO’s hyperbolic statements, with little to substantiate them subsequently. I would prefer to receive short progress reports informing investors at appropriate points during the execution of the latest strategy
I received this message today:
“Many thanks for your enquiry ……………….,
Interferon beta may have potential in a range of indications, including MS, for which patients take injected forms of IFN-beta, as highlighted in the article you have shared.
Synairgen remains focussed on developing SNG001 for the local affects of IFN-beta in the lungs for the treatment of severe viral lung infections. There are no current plans to target MS.
Best regards,
Lucy”
The summer months are usually a quiet period for most investments. It doesn’t prevent investors searching for positive news, which might affect their portfolios. I continue to do just that, in particular with Synairgen, for which my portfolio devaluation is currently the greatest.
It is unlikely that there will be meaningful developments for several months, until we receive an update about the commencement of the parallel P2 mini trials?
There has been practically no publicity on LinkedIn/ twitter since Brooke Clarke left the company. Was she also responsible for updating the website?
This is currently in need of attention. For example, the section on Corporate Governance. I refer to Principle 1, which is very important for investors. This has clearly not been updated from the time that the Sprinter trials were being conducted. This concludes with the following: “The strategy is reviewed annually and more frequently if circumstances dictate.”
Clearly, an area in need of attention for Mr. Shaw and the BOD perhaps?
I may be nitpicking here, but believe that future Synairgen investors are more likely to view the company seriously if the freely available information released by the company is regularly reviewed in line with the most recent developments.
Perhaps, I am grasping at straws here? Synairgen have established links, and potential partners in the US. I wonder whether they would be able to take advantage of this piece of legislation, bearing in mind the clearly identified need for their product? The well established safety record from previous SNG001 trials would be a major factor in any future trialling of this description.
https://www.congress.gov/bill/117th-congress/senate-bill/1644
The Promising Pathway Act is a new law designed to take drugs to patients much quicker. It does away with the need for a P3 trial. With conditional approval after P3, it cuts off 95% of developing the drug. Every patient that uses the drug while it’s conditionally approved has to be followed in a registry as if they’re in a clinical trial.
We are still not receiving the investor interest that this company surely now deserves? Evidence for its potential is being accumulated and regularly shared.
Am I being too optimistic in thinking that there are large entities who are probably interested in acquiring IB’s diversified portfolio?
Could the inhalation of nebulised IFN-β be applied in the treatment of MS? Has this been considered by Synairgen as part of their aspiration in moving towards developing their product as a broad spectrum treatment?
“The renewed interest in IFN biology related to viral infections has led to a deeper knowledge on the effects of these molecules on the immune system, which could be rapidly translated into practice thanks to solid experience in the MS field.”
https://www.frontiersin.org/articles/10.3389/fimmu.2023.1161849/full
It is probably best to green bin the short term sellers on this forum. It is obvious who they are!
One thing is certain. The market shenanigans that have surrounded this investment are not serving the best of interest of those of us who are adopting a long term hold strategy.
I can think of three occasions when I would have benefited enormously from selling “high” and buying back “low”.
It is probably high time for this company to deliver on its promises! LTHs have been on hold for a very long time. I am not in a poor position with this investment. However, to say that I am disappointed that promises given to investors have not yet been met in line with the company’s promoted
“expectations” is an important understatement!
My SNG investment “strategy” is, and always was, that described by Doc83 and Wigster. However, I would not recommend it to other investors, as their affairs are none of my business. Every investor presumably carries out their own research, and takes decisions based on the conclusions of that research.
My decision to hold all my SNG portfolio throughout the SNG0018 trial was a mistake. However, a long time ago, I decided that research concerning SNG001 conducted prior to the outcome of that trial wasn’t flawed.
I was under informed as to the company’s revised strategy until recently. Although nothing is certain, I am now relatively “optimistic” that we are back on track. Although far from being secure, my long term hold (3 years next August since my first shares purchase) has a chance of future success again. My thanks to everyone who reported back from the AGM. The detailed commentary on its proceedings, and on the nature of the next P2 trials, were invaluable in updating my knowledge about, and understanding of the company’s strategy.
Future success is a long term prospect. I am currently considering a time frame of at least another year, if not longer. The only issue that currently blights my horizon is that of funding. Despite the fact that the initial trials are funded from the company’s capital reserve, future funding remains uncertain? IMHO, successful readouts from the P2 trials should go a long way in securing future support? Like all investors, I will need to be patient and see what develops?
The LTIs, who gave up on Synairgen sold their holdings a long time ago. Any investors, who didn’t sell when the share price was in the 25p - 35p range last year are highly unlikely to do so now? It is far better to risk losing it all than to sell at the current price IMHO. Especially, if like me you believe that the share price will recover to a far higher level than is the case today?
I have been reading the latest company information carefully, and have consigned my SNG portfolio to the bottom drawer, probably until late 2024 - 2025. It is going to take a considerable time for the current strategy to fully evolve. Some support may be needed along the way? Or perhaps a different direction may be taken by the company if the P2 results show promise? Spacman’s prophecies may yet come to fruition? Who knows?
Any sensible investor would not dismiss SNG001 on the grounds that it is too expensive. The potential benefits of administering the drug would need to be carefully weighed against other available options for a particular situation.
Expert opinions testify that there is a need for an effective broad spectrum antiviral treatment. Statistics are quoted on the Synairgen website, and on multiple LinkedIn accounts.
Successful P2 trials could pave the way for its emergence as a necessary component of the vast toolkit of essential treatments?
There is a long wait ahead of us to be sure. It is best to avoid the meaningless comments from the unbelievers, purveyors of extreme negativity, and prophets of doom. They know as much and as little as I do about what the future may hold?
GLALTIs
The capital letters are being changed to lower case in my posts this morning? Is anyone else experiencing the same?
strange to see ********* for r.e.t.a.r.d.ing in my previous post? perhaps the inappropriate language filter originated in the usa? the word has a more offensive meaning over there.
glaltis.
this investment is heading in the right direction. this morning, we are seeing profit taking from traders, which is ******ing a more significant rise as a result of some buyers, who have decided to come on board.
more evidence is needed to tempt significant buyers and impart momentum on the share price rise. a matter of time imho, but i have little idea how long it will take before the share price will reach 0.25p (when i shall sell some of my shares)?
glaltis.
My thanks to all who attended the AGM for providing feedback. I have been out all day, and haven't yet had the time to read your comments. That will happen during the weekend.
I followed this board on my iPhone for part of the morning. In retrospect, I believe that some of my comments at the time were hasty, and badly-judged. Having looked at the presentation in greater detail, I now have a better understanding of Synairgen's strategy. It is going to take far longer than I had originally anticipated for the company to start making progress, but I am now happier with our situation than I have been for several months. The major issue, as I see it will be in securing appropriate funding to carry this research through to a conclusion. It is far too early to think about Phase III trials. For the time being, there is sufficient capital to commence with the initial parallel trials.
I am hoping that the coming year will be a better one for the company than the preceeding one. It is useful for investors to finally have an idea of the company's future direction.
GLALTIs.
The same thing is happening as during the debacle of the P2 Home Trial Webinar. They got away with that one, for obvious reasons.
Sadly, the CEO and his acolytes do not learn from past mistakes. His new year message gave the impression of being thrown together with little effort. These presentation slides are the same. They are similar to what are currently appearing in abundance on LinkedIn and elsewhere. They are not Synairgen specific. What happened to the corporate image that Brooke Clarke built on twitter/LinkedIn?